



## Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101  
Phones : ++ 91 - 172-2730503, 2730920, Fax ++ 91 - 172 - 2730504, 2736294  
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com  
CIN No. L24232CH1995PLC015553



Ref: ISLL:CH:2024

Date: 3<sup>rd</sup> April, 2024

**The President  
Corporate Relationship Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai 400 001**

**The Vice President,  
Listing Compliance Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5<sup>th</sup> Floor  
Plot No. C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051**

**ISIN: INE915B01019, INE915B07024  
BSE Scrip Code: 532305, 957989**

**NSE Symbol: INDSWFTLAB**

**Sub: Disclosure under Regulation 10(6)- Report to Stock Exchanges in respect of acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for inter-se transfer of shares between the promoters of the Company**

Dear Sir/ Madam,

With reference to the captioned subject please find the attached herewith, disclosure received by the Company from M/s. Essix Biosciences Limited, as per Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, in respect of acquisition of 94,99,720 (Ninety-Four Lakhs Ninety-Nine Thousand Seven Hundred and Twenty) equity shares of Ind-Swift Laboratories Limited by way of inter-se transfer among the promoters.

You are requested to take the same on record.

For **IND-SWIFT LABORATORIES LTD.**



**PARDEEP VERMA  
VP-CORPORATE AFFAIRS &  
COMPANY SECRETARY**

# Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)  
Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294  
Factory : Plot No. B-4 & 5, Industrial Focal Point, Derabassi, Punjab (India)  
Ph. 01762-281278, 79. CIN NO. U74999CH1993PLC033428

Ref.: EBL:CH:2024:

Date: April 02, 2024

The President,  
Corporate Relationship Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
25th Floor, Dalal Street,  
Mumbai 400 001

The Vice President,  
National Stock Exchange of India Limited,  
Exchange Plaza, 5th Floor,  
Plot No.C/2, G-Block,  
Bandra Kurla Complex, Bandra (E),  
Mumbai 400 051

Sub: Intimation of disclosure Disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Ref. Prior Intimation filed under Regulation 10(5) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 dated February 07, 2024

Respected Sir/Ma'am,

We are enclosing herewith the disclosure in the prescribed format as required under Regulation 10(6) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 in respect of inter-se off market acquisition of 94,99,720 shares of Ind-Swift Laboratories Limited.

You are requested to kindly take the same on record.

Thanking You.

For ESSIX BIOSCIENCES LIMITED

  
PANKAJ  
COMPANY SECRETARY  
ACS NO.- 68372




CC:  
Company Secretary  
Ind Swift Laboratories Limited  
SCO 850, Manimajra, Chandigarh.

Encl: As above

**Format for Disclosures under Regulation 10(6) –Report to Stock Exchanges in respect of any acquisition made in reliance upon exemption provided for in Regulation 10 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

1.	Name of the Target Company (TC)	IND-SWIFT LABORATORIES LIMITED			
2.	Name of the acquirer(s)	ESSIX BIOSCIENCES LIMITED			
3.	Name of the stock exchange where shares of the TC are listed	BSE LIMITED (BSE) AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED (NSE)			
4.	Details of the transaction including rationale, if any, for the acquisition of shares.	Acquisition By Way of Inter-Se Transfer			
5.	Relevant regulation under which the acquirer is exempted from making open offer.	Regulation 10(1)(a)(ii) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SAST”)			
6.	Whether disclosure of proposed acquisition was required to be made under regulation 10 (5) and if so, - whether disclosure was made and whether it was made within the timeline specified under the regulations. - date of filing with the stock exchange.	Yes, the disclosure was made within the timeline specified under the regulations.  February 07, 2024			
7.	Details of acquisition	Disclosures required to be made under regulation 10(5)	Whether the disclosures under regulation 10(5) are actually made		
	a. Name of the transferor / seller	IND-SWIFT LIMITED	IND-SWIFT LIMITED		
	b. Date of acquisition	March 28, 2024	March 28, 2024		
	c. Number of shares/ voting rights in respect of the acquisitions from each person mentioned in 7(a) above	94,99,720	94,99,720		
	d. Total shares actually acquired as a % of diluted share capital of TC	16.08%	16.08%		
	e. Price at which shares are actually acquired	Rs. 101/-	Rs. 101/-		
8.	Shareholding details	Pre-Transaction		Post-Transaction	
		No. of shares held	% w.r.t total share capital of TC	No. of shares held	% w.r.t total share capital of TC
	a Each Acquirer / Transferee(*)	12827787	21.71%	22327507	37.79%
	b Each Seller / Transferor	9499720	16.08%	0	0



**Note:**

- (\*) Shareholding of each entity shall be shown separately and then collectively in a group.
- The above disclosure shall be signed by the acquirer mentioning date & place. In case, there is more than one acquirer, the report shall be signed either by all the persons or by a person duly authorized to do so on behalf of all the acquirers.

**For ESSIX BIOSCIENCES LIMITED**

  
PANKAJ  
COMPANY SECRETARY  
ACS NO. 68372



**Place: Chandigarh**

**Date: 02.04.2024**

\*\*\*\*\*